# Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer

> **NCT06228053** · PHASE2 · RECRUITING · sponsor: **Syntrix Biosystems, Inc.** · enrollment: 53 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** SX-682
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT06228053
- **Lead sponsor:** Syntrix Biosystems, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-18
- **Primary completion:** 2026-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2025-12-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06228053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06228053, "Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06228053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*